People | March 14, 2023
Precision appoints John Hubbard, PhD, as Board of Directors Chair
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Subscribe To Our Newsletter & Stay Updated
